APRI Calculator
Calculate the AST to Platelet Ratio Index score and fibrosis risk interpretation from AST, AST upper limit of normal, and platelet count. APRI Calculator helps clinicians and patients screen for liver fibrosis and support hepatitis-related liver disease assessment.
Highlights
- Calculates the AST to Platelet Ratio Index (APRI) score.
- Uses AST level, AST upper limit of normal, and platelet count.
- Provides an estimate of liver fibrosis risk.
- Offers lower, indeterminate, or higher-risk interpretations.
- Supports noninvasive assessment of hepatitis-related liver disease.
Table of Contents
How APRI Calculator Works?
The AST to Platelet Ratio Index (APRI) estimates the likelihood of significant liver fibrosis using the measured aspartate aminotransferase (AST), the laboratory's AST upper limit of normal (ULN), and the platelet count. AST is first expressed relative to its laboratory reference limit, then divided by the platelet count.
In this formula, AST and the AST upper limit of normal are entered in U/L, while the platelet count is entered in 109/L (K/µL). The resulting APRI is a dimensionless score. A higher AST relative to its ULN increases the score, while a lower platelet count also increases it.
| APRI score | General interpretation |
|---|---|
| Less than 0.5 | Lower likelihood of significant fibrosis |
| 0.5 to 1.5 | Indeterminate likelihood; additional assessment may be needed |
| Greater than 1.5 | Higher likelihood of significant fibrosis |
For example, with an AST of 80 U/L, an AST upper limit of normal of 40 U/L, and a platelet count of 100 × 109/L, the calculation is (80 ÷ 40 × 100) ÷ 100 = 2.0. This falls in the higher-likelihood category. APRI is a screening and risk-stratification tool, not a standalone diagnosis.
Practical Use Cases
Hepatology clinicians can use APRI as a quick noninvasive screening measure when reviewing AST and platelet results in people with chronic liver disease or suspected fibrosis, helping determine whether further evaluation is appropriate.
Primary care clinicians can use the score to support the initial assessment of abnormal liver tests or possible hepatitis-related liver disease before referral or additional fibrosis testing.
Hepatitis care teams can calculate APRI during evaluation and follow-up to provide a simple, repeatable indicator alongside clinical history, laboratory findings, and disease-specific assessments.
Medical students and trainees can use the calculator to understand how AST elevation relative to its reference limit and reduced platelet count contribute to a noninvasive fibrosis score.
Patients reviewing laboratory results may use APRI to understand how selected blood-test values are combined, but the result should be discussed with a qualified healthcare professional rather than used for self-diagnosis.
Accuracy and Limitations
APRI is an estimate whose reliability depends on using the laboratory-specific AST upper limit of normal and platelet count from the same clinical evaluation. The score can be misleading when AST is elevated by acute hepatitis, alcohol use, muscle injury, medications, or other non-fibrosis causes, and platelet counts can be reduced by conditions unrelated to portal hypertension or liver fibrosis. Borderline results, particularly between 0.5 and 1.5, are indeterminate and should not be treated as definitive; APRI cannot stage fibrosis precisely, confirm cirrhosis, or replace clinical assessment, imaging, elastography, specialist review, or biopsy when indicated.
Quick Examples
Example #1: Normal Screening Profile
Example APRI calculation inputs for a patient with AST and platelet values within typical reference ranges.
Example #2: Mildly Elevated AST
Example inputs for evaluating fibrosis risk when AST is moderately elevated and platelet count is mildly reduced.
Example #3: Higher-Risk Liver Profile
Example APRI inputs showing substantially elevated AST and a low platelet count for liver fibrosis risk assessment.
